StreetInsider.com News Articles

Kura Oncology (KURA) Reiterated at Overweight by Cantor Fitzgerald After Webinar on KO-7246

Wed, 14 Oct 2026 07:19:39 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Kura Oncology (NASDAQ: KURA).

The analyst commented, "Kura and its spin-out, Caspian Therapeutics (pvt.), hosted a webinar providing the scientific rationale for the advancement of menin inhibitor KO-7246 in diabetes. The program is currently in IND-enabling studies; once completed, it will enter a healthy volunteer trial to assess the molecule's safety, tolerability, and PK profile before being tested in patients. Management does not expect the initial proof-of-concept (POC) data until late 2028/early 2029, which are expected to be funded by the initial $50M financing. Given Kura's ~50% stake in Caspian, we

Kura Oncology (KURA) Reiterated at Market Outperform by Citizens on Preclinical Data for KO-7246

Wed, 14 Oct 2026 04:17:30 -0400

Citizens analyst Reni J. Benjamin reiterated a Market Outperform rating and $24.00 price target on Kura Oncology (NASDAQ: KURA).

The analyst commented, " We reiterate our Market Outperform rating and $24 price target for Kura Oncology based on a discounted EPS and revenue multiple analysis. Yesterday, Kura and Caspian Therapeutics presented preclinical data for KO-7246, highlighting potential best-in-class menin inhibitor results for the treatment of diabetes. With the Ziftomenib launch and multiple registrational studies underway, updated ziftomenib combo data expected at ASH, the FTI platform to enter registrational studies in 2028, and a cash position of $519MM, we believe Kura shares

Kura Oncology and Caspian outline diabetes drug development plan

Tue, 13 Oct 2026 07:31:50 -0400

Kura Oncology (Nasdaq: KURA) and its spinout Caspian Therapeutics have detailed a development strategy for KO-7246, an oral menin inhibitor being evaluated as a potential treatment for diabetes, according to a press release from the companies.

Kura launched Caspian in September 2026 with $50 million in financing led by BVF Partners, with participation from T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of Kura's leadership team, and several biotech entrepreneurs. Kura contributed KO-7246 and related intellectual property to Caspian and retains approximately half ownership of the company.

The companies presented preclinical findings at the 62nd European Association for the

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

Tue, 13 Oct 2026 07:30:00 -0400

– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity –

– IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and endogenous insulin production –

– Investor webcast today, October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) plan to outline the development strategy for KO-7246, Caspian’s selective, oral menin inhibitor designed for diabetes and other chronic metabolic

Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes

Tue, 13 Oct 2026 07:30:00 -0400

– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity –

– IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and endogenous insulin production –

– Investor webcast today, October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –

Caspian Therapeutics and Kura Oncology to host investor webcast

Wed, 07 Oct 2026 07:15:13 -0400

Caspian Therapeutics, Inc. and Kura Oncology, Inc. (Nasdaq: KURA) announced they will host a joint investor webcast on Oct. 13, 2026, at 4:30 p.m. ET.

According to a press release, management from both companies will discuss the formation of Caspian and review preclinical data for KO-7246, which was featured in an oral presentation at the 62nd European Association for the Study of Diabetes Annual Meeting.

Caspian Therapeutics is a company focused on menin-directed therapies in diabetes and cardiometabolic diseases. Its lead compound, KO-7246, is an oral menin inhibitor currently in IND-enabling development. The company plans to evaluate KO-7246 in a Phase 1

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

Wed, 07 Oct 2026 07:15:00 -0400

SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced they will host an investor webcast on Tuesday, October 13 at 4:30 p.m. ET. On the call, management from the companies will provide details regarding the formation of Caspian and will also review KO-7246 data featured in an oral presentation at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting.

Virtual Investor Event

Caspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

Wed, 07 Oct 2026 07:15:00 -0400

Virtual Investor Event

Caspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30

UBS Reiterates Buy Rating on Kura Oncology (KURA)

Mon, 05 Oct 2026 05:37:17 -0400

UBS analyst David Dai reiterated a Buy rating and $15.00 price target on Kura Oncology (NASDAQ: KURA).

The analyst comments "KURA's 2Q26 metrics reinforced strong early Komzifti launch execution, with accelerating new patient starts, growing repeat prescribing, and favorable access dynamics supporting continued uptake. Management increasingly emphasized Komzifti's potential as a frontline AML backbone therapy, citing high current combination use (~40%), upcoming FLT3 combination data, encouraging frontline efficacy, and the prospect for multi-year treatment duration. Despite growing competition, mgmt remains confident that Komzifti's tolerability, combination flexibility, and clean long-term safety profile will become increasingly important differentiators as menin inhibitors move earlier

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 07:30:00 -0400

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 07:30:00 -0400

JPMorgan Starts Kura Oncology (KURA) at Overweight

Thu, 01 Oct 2026 02:43:34 -0400

JPMorgan analyst Priyanka Grover initiates coverage on Kura Oncology (NASDAQ: KURA) with a Overweight rating and a price target of $30.00.

The analyst comments: “Our Overweight thesis centers on Kura Oncology’s transition into a commercial-stage oncology company with Komzifti (ziftomenib) in relapsed / refractory (r/r) NPM1-mutant AML, with a clinical profile that expands potential use from monotherapy to a combination agent across the AML regimens already in use by physicians. A clean label with manageable safety, low differentiation syndrome, and importantly no ziftomenib-related QTc black-box warning is a clear differentiator among the menin class. Paired with once-daily oral dosing and a

JPMorgan Starts Kura Oncology (KURA) at Overweight

Thu, 01 Oct 2026 02:43:34 -0400

JPMorgan analyst Priyanka Grover initiates coverage on Kura Oncology (NASDAQ: KURA) with a Overweight rating and a price target of $30.00.

Form 4 Kura Oncology, Inc. For: Sep 28 Filed by: Leoni Mollie